Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;5(2):E14.
doi: 10.1208/ps050214.

Iontophoretic transdermal delivery of buspirone hydrochloride in hairless mouse skin

Affiliations

Iontophoretic transdermal delivery of buspirone hydrochloride in hairless mouse skin

Mohammad Al-Khalili et al. AAPS PharmSci. 2003.

Abstract

The transdermal delivery of buspirone hydrochloride across hairless mouse skin and the combined effect of iontophoresis and terpene enhancers were evaluated in vitro using Franz diffusion cells. Iontophoretic delivery was optimized by evaluating the effect of drug concentration, current density, and pH of the vehicle solution. Increasing the current density from 0.05 to 0.1 mA/cm2 resulted in doubling of the iontophoretic flux of buspirone hydrochloride, while increasing drug concentration from 1% to 2% had no effect on flux. Using phosphate buffer to adjust the pH of the drug solution decreased the buspirone hydrochloride iontophoretic flux relative to water solutions. Incorporating buspirone hydrochloride into ethanol:water (50:50 vol/vol) based gel formulations using carboxymethylcellulose and hydroxypropylmethylcellulose had no effect on iontophoretic delivery. Incorporation of three terpene enhancers (menthol, cineole, and terpineol) into the gel resulted in a synergistic effect when combined with iontophoresis. Menthol was the most active enhancer, and when combined with iontophoresis it was possible to deliver 10 mg/cm2/day of buspirone hydrochloride.

PubMed Disclaimer

References

    1. Balon R. Buspirone in the treatment of separation anxiety in an adolescent boy. J Clin Psychopharmacol. 1994;14:360–361. doi: 10.1097/00004714-199410000-00016. - DOI - PubMed
    1. Ratey JJ, Sovner R, Mikkelsen E, Chmielinski HE. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry. 1989;50:382–384. - PubMed
    1. Realmuto GM, August GJ, Garfinkel BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol. 1989;9:122–125. doi: 10.1097/00004714-198904000-00009. - DOI - PubMed
    1. Dollery C. Therapeutic Drugs. 2nd ed. Edinburgh, Scotland: Churchill Livingston; 1999.
    1. Valenta C, Siman U, Kratzel M, Hadgraft J. The dermal delivery of lignocaine: influence of ion pairing. Int J Pharm. 2000;197:77–85. doi: 10.1016/S0378-5173(99)00453-6. - DOI - PubMed

LinkOut - more resources